Abstract:The inflicted chaos instigated by the SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) globally continues with the emergence of novel variants. The current global outbreak is aggravated by the manifestation of novel variants, which affect the effectiveness of the vaccine, attachment with hACE2 (human Angiotensin-converting enzyme 2) and immune evasion. Recently, a new variant named University Hospital Institute (IHU) (B.1.640.2) was reported in France in November 2021 and is spreading globally affecting public healthcare. The B.1.640.2 SARS-CoV-2 strain revealed 14 mutations and 9 deletions in spike protein. Thus, it is important to understand how these variations in the spike protein impact the communication with the host. A protein coupling approach along with molecular simulation protocols was used to interpret the variation in the binding of the wild type (WT) and B.1.640.2 variant with hACE2 and Glucose-regulating protein 78 (GRP78) receptors. The initial docking scores revealed a stronger binding of the B.1.640.2-RBD with both the hACE2 and GRP78. To further understand the crucial dynamic changes, we looked at the structural and dynamic characteristics and also explored the variations in the bonding networks between the WT and B.1.640.2-RBD (receptor-binding domain) in association with hACE2 and GRP78, respectively. Our findings revealed that the variant complex demonstrated distinct dynamic properties in contrast to the wild type due to the acquired mutations. Finally, to provide conclusive evidence on the higher binding by the B.1.640.2 variant the TBE was computed for each complex. For the WT with hACE2 the TBE was quantified to be-61.38 +/- 0.96 kcal/mol and for B.1.640.2 variant the TBE was estimated to be -70.47 +/- 1.00 kcal/mol. For the WT-RBD-GRP78 the TBE -was computed to be 32.32 +/- 0.56 kcal/mol and for the B.1.640.2-RBD a TBE of -50.39 +/- 0.88 kcal/mol was reported. This show that these mutations are the basis for higher binding and infectivity produced by B.1.640.2 variant and can be targeted for drug designing against it.Communicated by Ramaswamy H. Sarma

Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation

Computational analysis of affinity dynamics between the variants of SARS-CoV-2 spike protein (RBD) and human ACE-2 receptor

Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2

Computational Prediction of the Effect of Mutations in the Receptor-Binding Domain on the Interaction Between SARS-CoV-2 and Human ACE2

Molecular Insights into the Variability in Infection and Immune Evasion Capabilities of SARS-CoV-2 Variants: A Sequence and Structural Investigation of the RBD Domain

SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy

A Comparative Analysis of SARS-CoV-2 Variants of Concern (VOC) Spike Proteins Interacting with hACE2 Enzyme

Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant

Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor

Molecular insights into the binding interactions and energetics of the omicron spike variant with hACE2 and a neutralizing antibody

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2

Exploring the Binding Affinity and Mechanism between ACE2 and the Trimers of Delta and Omicron Spike Proteins by Molecular Dynamics Simulation and Bioassay

The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data

Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2

Structural and Computational Insights into the SARS-CoV-2 Omicron RBD-ACE2 Interaction

Insights from In Silico Study of Receptor Energetics of SARS-CoV-2 Variants

Structure-based drug discovery to identify SARS-CoV2 spike protein-ACE2 interaction inhibitors

Structural Basis for the Mechanism of Interaction of SARS-CoV-2 B.1.640.2 Variant RBD with the Host Receptors Hace2 and GRP78.

Subtle changes at the RBD/hACE2 interface during SARS-CoV2 variant evolution: a molecular dynamics study

Unraveling the binding mechanisms of SARS-CoV-2 variants through molecular simulations

Binding Affinity and Mechanisms of SARS-CoV-2 Variants